| Title： | Vancomycin Adults Dosing and Monitoring Guidelines |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Comprehensive guideline |
| Countries and regions： | Saudi Arabia |
| Guidelines users： | All clinical specialties involved in ordering, monitoring or dispensing of Vancomycin including: clinical pharmacists, physicians, nurses, and pharmacists |
| Evidence classification method： | The description of the methodology for the production of this adapted CPG can be fulfilled by utilizing the King Saud University (KSU) Modified ADAPTE method. This CPG formal adaptation method included three phases (setup, adaptation, and finalization), nine modules, and 24 steps with modifications in the steps and tools to suit the local general healthcare setting in Saudi Arabia. Overall, the steps of CPG adaptation included the selection of the health topic, formulation of the CPG adaptation working group, identification of health questions using the PIPOH model, searching and selecting Source CPGs with clear inclusion and exclusion criteria, quality assessment of included Source CPGs by using the Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument, assessment of the currency of the selected Source CPG, drafting of the adapted CPG, external review and consultation process, finalization of the adapted CPG with a set of implementation tools, declaration of conflicts of interests, and finally a plan for review and update. For further details on the specific modifications in steps and tools, refer to the article by Amer et al. 2019 (https://doi.org/10.1111/jep.12927). |
| Development unit： | King Saud University Medical City (KSUMC) |
| Registration time: | 2022-08-15 |
| Registration number： | PREPARE-2022CN504 |
| Purpose of the guideline: | To provide guidance for physicians, nurses, clinical pharmacists and pharmacists in KKUH/KAUH to help them in making clinical decisions on dosing and monitoring of Vancomycin in the treatment of adult patients with gram positive infections susceptible to Vancomycin, in order to lower the risk of both treatment failure, and associated incidence of resistance, and preventing side effects (nephrotoxicity and/or ototoxicity). |
Latest registration
